Emulate

Develops Organ-on-a-Chip technology for drug research

Boston, Massachusetts, United States

About Emulate

Emulate Bio focuses on improving drug development in the pharmaceutical and healthcare sectors through its Organ-on-a-Chip technology. This technology mimics human biology more accurately than traditional methods, allowing researchers to better understand how drugs interact with the human body. Emulate Bio offers a platform that includes instruments, consumables, and software, making it easier for researchers and pharmaceutical companies to develop safer and more effective drugs. Unlike competitors, Emulate Bio emphasizes a flexible, open format that enhances collaboration and understanding in drug research. The company's goal is to enhance human health and safety by improving the success rates of clinical trials and drug development processes.

Boston, MassachusettsHeadquarters
2014Year Founded
$245.9MTotal Funding
SERIES_FCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Risks

Competition from similar biotechnology firms may erode Emulate's market share.
Rapid technological advancements could render Emulate's offerings obsolete.
Ethical concerns and regulatory scrutiny may delay product approvals.

Differentiation

Emulate's Organ-on-a-Chip technology surpasses traditional animal models in accuracy.
The Chip-R1(TM) Rigid Chip minimizes drug absorption, enhancing biological modeling.
Emulate's Liver-Chip improves drug safety predictions, reducing clinical trial failures by 87%.

Upsides

Increased adoption of Organ-on-a-Chip technology boosts Emulate's market position.
$82 million Series E funding supports product expansion and research enhancement.
Recognition as a top innovative company enhances Emulate's brand reputation.

Funding

Total raised$245.90 M
Latest valuation$410.00 M
StageSERIES_F
SERIES F
2/29/2024
$47
$410.00 M
$82
$410.00 M
DEBT
2/29/2020
$19
$28
$139.95 M
SERIES A
6/30/2014
$12
$60.00 M